Pharmafile Logo
Pharmafocus logo
Advanced Search

rivaroxaban

Showing 7 posts of 7 posts found.

Xarelto

Investigation questions Xarelto trial data accuracy

February 4, 2016
Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …

News
Xarelto

Bayer backs safety of Xarelto after real-world data study

September 2, 2015
Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban

Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …

News
Xarelto image

Bayer promotes Xarelto benefits

June 15, 2015
Sales and Marketing Bayer, Eliquis, Xarelto, blood, law suits, rivaroxaban

Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …

News
Bayer image

Bayer launches major new stroke trial

January 27, 2015
Research and Development, Sales and Marketing Bayer, Canadian Stroke Prevention Intervention Network, Population Health Research Institute, Xarelto, rivaroxaban, stroke

Bayer is enrolling more than 7,000 people in a trial to test whether its blood-thinning drug Xarelto can successfully prevent …

News
Xarelto image

NICE recommends Bayer heart attack drug

January 26, 2015
Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban

NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …

News
Xarelto, bayer, ACS, janssen, fda, asa, blood

Bayer ‘disappointed’ with FDA

February 18, 2014
Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban

Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …

News

Bayer submits new Xarelto indications for European approval

January 6, 2011
Sales and Marketing Bayer, DVT, Xarelto, atrial fibrillation, deep vein thrombosis, pulmonary embolism, rivaroxaban, stroke prevention

Bayer is seeking European regulatory approval for a batch of new indications for its oral anticoagulant Xarelto. The company is …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025